Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | KHK | P50053 | 4/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 9/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 9/20 | 0.39 |
| ▸ | KDM5A | P29375 | 8/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4558167 | 0.89 | KDM5A (0.45) | RARGKDM4CKDM5BKDM5A | |
| SCHEMBL14032596 | 0.85 | KHK (0.42) | KHKHDAC8FFAR4MAPK14 | |
| SCHEMBL8268988 | 0.85 | KHK (0.41) | KHKHDAC8MAPK14 | |
| SCHEMBL3607823 | 0.84 | KHK (0.41) | KHKSLC22A12 | |
| SCHEMBL3602376 | 0.83 | PTGS2 (0.41) | KHKKDM4CKDM5BKDM5AMAPK14 | |
| SCHEMBL3599265 | 0.82 | PTGS2 (0.44) | HDAC8MAPK14 | |
| SCHEMBL3604665 | 0.81 | RARG (0.42) | RARGRORCKDM4CKDM5BKDM5A | |
| SCHEMBL4261343 | 0.78 | SLC22A12 (0.60) | RARGRORCSLC22A12 | |
| SCHEMBL27721970 | 0.76 | KDM5A (0.45) | RARGKHKKDM4CKDM5BKDM5A | |
| SCHEMBL3596448 | 0.76 | KHK (0.39) | KHKFFAR4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | claimed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | claimed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | claimed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | claimed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723348-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432266-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN | 2008-08-28 | — | — | US | disclosed |
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-01 | — | — | US | disclosed |
| EP-1799673-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2006-07-13 | — | — | US | disclosed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006044528-A1 | PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254913-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | RARG 790/4885RORC 961/4885KHK 997/4885 |
| US-20080207660-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE12 | RARG 790/4885RORC 961/4885KHK 997/4885 |
| US-20060154960-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | RARG 790/4885RORC 961/4885KHK 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.